Expert Review: Beyond Second-Line Treatment for Metastatic Breast Cancer - priME Oncology
Expert Review
Expert Review

Expert Review: Beyond Second-Line Treatment for Metastatic Breast Cancer

Not a member of My prIME? Join now for instant access.

Expert Review: Beyond Second-Line Treatment for Metastatic Breast Cancer

View Activity

Activity Overview

This CME-certified Expert Review, featuring an interactive video with clinical opinion poll questions and downloadable slides, focuses on the treatment of metastatic breast cancer, specifically beyond second-line treatment.

MODERATOR

  • Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
    University of Sheffield
    Weston Park Hospital
    Sheffield, United Kingdom

DISCUSSANTS

  • Joyce O’Shaughnessy, MDBaylor University Medical Center
    Texas Oncology
    US Oncology
    Dallas, Texas, United States
  • Denise Yardley, MDSarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee, United States

Topics

  • Chemotherapy for advanced breast cancer, particularly beyond second-line, for patients with estrogen receptor–positive and triple-negative breast disease
  • Goals of chemotherapy beyond second-line
  • Selection of optimal therapy
  • Balancing treatment efficacy and adverse event management
  • Agents used beyond the second-line, including epothilones
  • Ongoing trials
  • Novel agents

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Incorporate therapies for advanced/metastatic breast cancer into individualized treatment plans for patients based upon an evaluation of efficacy and safety data, as well as patient and tumor characteristics
  • Assess clinical trial data for the use of epothilones in (neo)adjuvant therapy and combinations with targeted treatment
  • Identify common or significant adverse events associated with treatment of advanced/metastatic breast cancer beyond the second-line setting, and the effective strategies for their prevention and/or management

Target Audience

This educational activity is specifically designed for medical oncologists, fellows, nurses, physician assistants, nurse practitioners, and other healthcare providers who treat/manage patients with metastatic breast cancer.

View Activity

Provider

This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

accme

prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Support

This educational activity is supported by a grant from R-Pharm US.

Activity Date

RELEASE DATE
March 2, 2016

EXPIRATION DATE
October 31, 2017